New Head and Neck Cancer Therapy Shows Promise
A new combination therapy shows potential for adults with advanced head and neck cancer in early-stage study results.
Updated on Oct. 25, 2026 in Cancer
Live Poll
Do you believe new pharmaceutical combinations are making treatment more effective for advanced cancer patients?
New trial results suggest that an experimental combination therapy including subcutaneous amivantamab shows promise for patients with advanced head and neck cancer. This treatment regimen is currently being evaluated for those with previously untreated recurrent or metastatic disease.
Why it matters
The study offers a potential new treatment pathway for head and neck squamous cell carcinoma, a cancer where effective options for advanced or recurrent cases are often limited. This development highlights ongoing efforts to improve outcomes by targeting specific drivers of tumor growth.
In a trial of 30 patients with previously untreated head and neck squamous cell carcinoma, the combination of subcutaneous amivantamab, pembrolizumab, and carboplatin yielded an overall response rate of 77% after a median follow-up of 10.6 months.
The players
Johnson and Johnson
A global pharmaceutical company developing therapies for complex diseases including various oncology treatments.
The details
The treatment works by targeting EGFR and MET signaling pathways, which often fuel tumor growth and facilitate resistance to existing therapies. Administered via subcutaneous injection every three weeks, the drug aims to disrupt these critical pathways while being combined with established cancer-fighting agents. The trial monitored side effects, with common adverse events reported including anaemia, hypoalbuminaemia, thrombocytopenia, and stomatitis.
Timeline
October 25, 2026: Results were presented at the ESMO Congress 2026.
Health Landscape
This study marks a significant step in the investigation of antibody-based combinations for head and neck cancer. It builds upon current research efforts aimed at overcoming tumor resistance mechanisms in recurrent or metastatic squamous cell carcinomas.
Patients with head and neck cancer should discuss these evolving research findings with an oncologist to understand how they may inform future care decisions. It is important to note that these are preliminary findings from a small group, and patients should consult their medical team about currently approved options.
The takeaway
While the 77% response rate in this small group is encouraging, further research is required to validate long-term survival outcomes for this therapy. Patients interested in emerging treatments should ask their physicians about ongoing clinical trial opportunities for their specific cancer stage.
What happens next
Johnson and Johnson plans to continue evaluating subcutaneous amivantamab in a larger Phase 3 clinical trial.
Further reading
For more information on current treatment trends, visit our Cancer section.
More information
Review the full details of the study on the OrigAMI-4 clinical trial registry page.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe new pharmaceutical combinations are making treatment more effective for advanced cancer patients?
